Skip to main content

Table 1 Clinicopathologic characteristics of patients

From: Metabolic phenotypes in primary unknown metastatic carcinoma

Clinical parameters

Total N = 77 (%)

Histologic subtype

p-value

AD (n = 27) (%)

PD (n = 16) (%)

SQ (n = 20) (%)

UD (n = 14) (%)

Age (years, mean ± SD)

55.4 ± 11.8

59.3 ± 12.3

55.3 ± 12.1

55.0 ± 9.6

48.3 ± 10.6

0.042

Sex

     

0.521

 Female

29 (37.7)

13 (48.1)

6 (37.5)

6 (30.0)

4 (28.6)

 

 Male

48 (62.3)

14 (51.9)

10 (62.5)

14 (70.0)

10 (71.4)

 

Clinical subtype

     

<0.001

 Nodal type

34 (44.2)

3 (11.1)

8 (50.0)

14 (70.0)

9 (64.3)

 

 Single organ type

15 (19.5)

6 (22.2)

5 (31.3)

0 (0.0)

4 (28.6)

 

 Intermediate type

14 (18.2)

7 (25.9)

1 (6.3)

5 (25.0)

1 (7.1)

 

 Carcinomatosis type

14 (18.2)

11 (40.7)

2 (12.5)

1 (5.0)

0 (0.0)

 

Organs involved

     

0.102

 Lymph node

49 (63.6)

12 (44.4)

9 (56.3)

19 (95.0)

9 (64.3)

 

 Bone

10 (13.0)

6 (22.2)

2 (12.5)

0 (0.0)

2 (14.3)

 

 Brain

9 (11.7)

4 (14.8)

2 (12.5)

1 (5.0)

2 (14.3)

 

 Other

9 (11.7)

5 (18.5)

3 (18.8)

0 (0.0)

1 (7.1)

 

Postoperative treatment

     

0.039

 None

21 (27.3)

8 (29.6)

3 (18.8)

4 (20.0)

6 (42.9)

 

 Chemotherapy

24 (31.2)

12 (44.4)

5 (31.3)

3 (15.0)

4 (28.6)

 

 Radiation therapy

15 (19.5)

6 (22.2)

1 (6.3)

6 (30.0)

2 (14.3)

 

 Chemo-radiation therapy

17 (22.1)

1 (3.7)

7 (43.8)

7 (35.0)

2 (14.3)

 
  1. PD: poorly differentiated carcinoma, AD: adenocarcinoma, SQ: squamous cell carcinoma, UD: undifferentiated carcinoma.
  2. Bold represents p<0.05.